428 results about "CSF - Cerebrospinal fluid" patented technology

The invention belongs to the technical field of nerve regulation and control engineering, and provides a cerebrospinal fluid rhythm-based Alzheimer's disease electrical stimulation system, which is characterized in that first frequency band range data and second frequency band range data in brain wave signals are coupled to obtain cerebrospinal fluid rhythm data; then, calculating the phase difference between the first frequency band range data and the cerebrospinal fluid rhythm data; finally, the stimulation frequency is dynamically controlled according to the phase difference, and the stimulation current is dynamically controlled according to the brain tissue water volume fraction. The problem that specific metabolism requirements of non-fast eye movement sleep and fast eye movement sleep cycles cannot be matched by adopting single-frequency-band stimulation is solved, dynamic changes of post-traumatic encephaledema and requirements and influences of cerebrospinal fluid rhythm on current control are considered, the real-time adaptive capacity to the dynamic changes of the post-traumatic encephaledema is improved, and the application prospect is wide. And the treatment effect of the Alzheimer's disease is ensured.

The invention provides an implantable nerve probe integrated with a biological protection layer, a preparation method and a system. The nerve probe sequentially comprises a bottom biological protection layer, a bottom flexible substrate layer, a conductive layer, a top flexible substrate layer and a top biological protection layer from bottom to top, the bottom biological protection layer and the top biological protection layer form a biological protection layer located on the outermost periphery of the nerve probe and are used for avoiding erosion of a damp and hot cerebrospinal fluid environment in brain tissue. The integrated biological protection layer located on the outermost periphery of the flexible nerve probe is adopted, corrosion of cerebrospinal fluid to the nerve probe can be inhibited in in-vivo application, the long-term biocompatibility of the flexible nerve probe is effectively improved, the in-vivo long-term service life of the flexible nerve probe is effectively prolonged, and the nerve probe has the advantages of being high in integration level, high in stability and the like; and the requirement of in-vivo long-term effective service of the device can be met.

The invention discloses a mouse spinal cord flexible electrode and a stimulation parameter optimization method, and relates to the technical field of parameter optimization. The mouse spinal cord flexible electrode comprises a soluble insertion layer, a gradient substrate layer, spinal cord anastomosis ribs, a conductive snakelike net, a hemispherical touch dot matrix, a microfluidic layer, an optical waveguide layer and a top packaging layer; the soluble insertion layer is photo-crosslinked PEG-DMA with the thickness of 5-25 m, the Young modulus is kept within the range of 0.8-1.5 GPa before implantation, and the soluble insertion layer is hydrolyzed in cerebrospinal fluid within 0.5-3 hours after implantation and completely falls off; the spinal cord anastomosis rib comprises an expandable S-shaped folding structure arranged on the upper surface of the gradient substrate layer, the distance between every two adjacent ribs ranges from 80 m to 200 m, the height of the folded state is not larger than 15 m, the height of the unfolded state ranges from 15 m to 40 m, and the spinal cord anastomosis rib is used for forming a cerebro-spinalfluid bypass groove extending in the longitudinal direction of the spinal cord on the surface of the dura mater. According to the invention, the positioning precision, safety and long-term efficiency of mouse spinal cord electrical stimulation can be effectively improved.

The invention provides a cerebrospinal fluid peritoneal shunt peritoneal section endoscope assist device, and relates to the technical field of medical instruments, the endoscope assist device comprises a cerebrospinal fluid peritoneal shunt tube, the endoscope assist device comprises a puncture sheath shell, the periphery of the cerebrospinal fluid peritoneal shunt tube is wrapped with the puncture sheath shell, and a strip-shaped clamping groove is formed in the periphery of the puncture sheath shell; the strip-shaped insertion plate is connected with the strip-shaped clamping groove in a sliding mode, and the strip-shaped insertion plate is connected with the puncture sheath shell through a locking piece; an endoscope channel is arranged on the inner wall of the strip-shaped insertion plate and is used for mounting an endoscope; the puncture sheath shell is inserted into the abdominal cavity, a guiding effect is achieved when the cerebrospinal fluid peritoneal shunt tube enters the abdominal cavity, and due to the design that the puncture sheath shell and the strip-shaped inserting plate can be opened and closed, the puncture sheath shell can be conveniently separated from the cerebrospinal fluid peritoneal shunt tube through the strip-shaped clamping groove.

The invention relates to the technical field of drainage control, in particular to an intelligent cerebrospinal fluid drainage rate and pressure cooperative control system and method. The system comprises a drainage pipeline module, a positioning adjustment module, an intelligent pump control module, a monitoring sensing module, a cooperative control module and a man-machine interaction module, and can be used for establishing a cerebrospinal fluid drainage channel and being connected with a drainage bag; a laser positioning pen fixed on the infusion rod emits a laser beam which is horizontal to a preset drainage plane and adjusts the hanging height; an infusion pump and a pump body controller drive cerebrospinal fluid to flow according to set parameters and generate flow velocity, flow and drainage time control signals, meanwhile, real-time intracranial pressure data, real-time flow and flow velocity data and physical sign data are collected, and a drainage height adjusting instruction or a pump control parameter adjusting instruction is generated; cooperative control over the drainage rate and the intracranial pressure is achieved, and system operation parameters, patient monitoring data and the drainage state are displayed. The drainage device can accurately control the drainage amount of cerebrospinal fluid.

Provided herein are methods and immune biomarkers that identify progression and treatment options for multiple sclerosis (MS). Also provided are materials and methods for the prognosis, staging, and monitoring of MS in a sample and include methods of determining a subject as being at risk of developing MS. The methods include detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3 in cerebrospinal fluid (CSF) in the subject; and administering a pharmaceutically effective amount of a treatment (e.g., tolebrutinib and potentially one or more additional therapies, such as an anti-CD20 therapy) to the subject.

The invention relates to a heterogeneous human head model construction method and system oriented to multi-physics field simulation, based on real human head T1 weighted magnetic resonance image data, key tissues such as white matter, gray matter and cerebrospinal fluid are accurately segmented, and a three-dimensional geometric model used for generating carrying tissue identification information is researched and developed; converting the model data into a file format conforming to the NASTRAN standard by utilizing an independently developed format conversion program, and completely retaining organization classification information; finally, different tissue areas are automatically recognized through physical field simulation software, corresponding frequency dependent material attributes are distributed, and a finite element model capable of being directly used for simulation is formed. According to the method, seamless integration of the high-precision heterogeneous human head model and the simulation platform is achieved, tedious manual repairing and assignment operation is not needed, the method has the advantages of being high in precision, high in efficiency and good in compatibility, and the authenticity and reliability of biomedical simulation such as transcranial magnetic stimulation and radio frequency coil design can be remarkably improved.

The invention discloses a brain-computer interface signal enhancement and evaluation method fusing physical information. The method comprises the following steps: firstly, based on an individual structure magnetic resonance image, constructing a personalized six-layer brain tissue anatomical model comprising a cortex, a white matter, cerebrospinal fluid, a dura mater, a skull and a scalp, and endowing differentiated conductivity parameters; secondly, neuroelectrophysiology priori knowledge such as neurodynamics and white matter anisotropic conduction is converted into a representation rule which can be learned by a neural network; then, the rules are systematically embedded into a physical information neural network in a differentiable physical constraint form, including a cortical neurodynamic equation residual error, a volume conduction equation residual error of each layer and an interlayer interface continuity constraint; and finally, training a network by using the scalp electroencephalogram signals, and jointly outputting high-fidelity intracranial electroencephalogram signals and multi-modal neurophysiological information by minimizing a loss function containing reconstruction and physical constraints. According to the method, the fidelity, the physical rationality and the clinical interpretability of signal enhancement are effectively improved.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting apolipoprotein E4 and application of the monoclonal antibody combination. The combination comprises a monoclonal antibody 4E10 and a monoclonal antibody 3H7, and complementary determining region (CDR) sequences of the monoclonal antibody 4E10 and the monoclonal antibody 3H7 are shown as SEQ ID NO.1 to SEQ ID NO.12. In double-antibody sandwich ELISA, 4E10 is used as a coating antibody, 3H7 is used as a labeled antibody, APOE4 subtypes can be effectively recognized, high-specificity and high-sensitivity detection of APOE4 can be achieved, the detection limit reaches 100 pg / mL, and the kit is suitable for quantitative detection of APOE4 in samples such as serum and cerebrospinal fluid. The method provides a reliable immunological tool for early risk assessment of the Alzheimer's disease, and has important clinical application value.

The invention relates to an instrument for transferring cerebrospinal fluid in a ventricle into a body cavity of other parts of a human body, and particularly discloses an intraventricular hydrops drainage device which comprises a base used for being attached to a bone window of a skull, a confluence cavity and a liquid outlet connector communicated with the confluence cavity are arranged on the base, and the liquid outlet connector is provided with a liquid inlet and a liquid outlet. The flow guide hose is connected to the liquid outlet joint; a tip axially remote from the base; the drainage main body component is used for guiding cerebrospinal fluid in the ventricle to the confluence cavity; the drainage main body component comprises a plurality of micro-catheters; the near end and the far end of each micro catheter are attached to the base and the end respectively, and the near end of the micro central hole of each micro catheter is communicated with the confluence cavity; the micro-conduits are arranged in a plurality of circles in the circumferential direction and the radial direction; a micro drainage structure communicated with the micro central hole is arranged on the tube wall of each micro catheter, and the micro drainage structures are arranged in the circumferential direction and the axial direction of the tube wall of the micro catheter so as to allow cerebrospinal fluid to enter the micro central hole through the tube wall of the micro catheter.

The invention provides a nomeline nasal-brain delivery preparation for transnasal region mucosa administration, and an auxiliary material mixture of the nasal-brain delivery preparation comprises 1) phospholipid, and 2) any one of diluent ethyl oleate, isopropyl myristate, sesame oil or castor oil; optionally, the auxiliary material mixture can also comprise 3) a dissolving agent such as ethanol or diethylene glycol monoethyl ether, the auxiliary material mixture is a non-aqueous system, and a solution prepared from the mixture of the two or three auxiliary materials can be absorbed by the nasal meatus olfactory mucosa after being administrated through the nasal region mucosa, can be quickly conducted to the brain olfactory bulb region along olfactory nerves and cerebrospinal fluid, and can be used for treating the brain olfactory bulb. The problems that the peripheral side effect is high due to poor brain targeting of the medicine, the medicine takes effect slowly and the like are solved.

The invention relates to the technical field of medical data processing, in particular to an intelligent drainage method and system based on cerebrospinal fluid pressure, and the method comprises the steps: obtaining a pressure signal curve and a pulse period of a cerebrospinal fluid intelligent drainage system at each detection position; obtaining a synchronous conduction error value according to the signal change trend in the pulse period of the to-be-analyzed signal curves of each detection position and other detection positions in combination with the signal change trend between the historical signal curves; according to the signal delay condition between pulse periods in the signal curve to be analyzed of each detection position and other detection positions, combining the signal delay condition of the historical signal curve to obtain a signal delay characteristic value; according to the synchronous conduction error value, the signal delay characteristic value and the signal change trend, analyzing the signal artifacts of each pulse period in the signal curve to be analyzed to obtain an artifact-removed signal; the de-artifact signal is used for a drainage operation. According to the invention, the occurrence of misrecognition is reduced, and the reliability of intelligent drainage decision is ensured.

Disclosed in the present invention are a preparation method for a brain-targeting agomelatine nasal spray micelle and use thereof, which belong to the technical field of pharmaceutical formulations. According to the present invention, an injectable pharmaceutical excipient polyethylene glycol (15)-hydroxystearate (HS15) is taken as a carrier material, HS15 and agomelatine are dissolved in an organic solvent, and the resulting solution is subjected to rotary evaporation under reduced pressure to form a uniform film, which, upon hydration, forms an agomelatine micelle solution capable of being sprayed nasally for treating depression and insomnia. According to the present invention, the problem of low oral bioavailability of agomelatine due to poor solubility, serious first pass effect of hepar, difficulty in penetrating a blood-brain barrier, etc., is solved. The micelle structure constructed in the present invention is quickly delivered into the brain after nasal administration, and it is stable in cerebrospinal fluid and can achieve slow release of the drug, thereby improving the intracerebral bioavailability of the drug and achieving high brain targeting property and low systemic toxic and side effects. The micelle structure has good clinical application value and market prospects.

The invention relates to the technical field of biology, in particular to an Alzheimer disease auxiliary detection kit based on a cerebrospinal fluid sample alpha-synuclein seed amplification technology and application of the Alzheimer disease auxiliary detection kit. The Alzheimer disease auxiliary detection kit based on the cerebrospinal fluid sample alpha-synuclein seed amplification technology comprises a substrate protein, a reaction reagent, a negative reference substance and a positive reference substance, and the sample is a to-be-detected cerebrospinal fluid sample. Cerebrospinal fluid of a subject is used as a detection sample for the first time, and clinical diagnosis research on the Alzheimer's disease by the RT-QuIC technology is carried out. The kit has obvious advantages in the aspects of high sensitivity, specificity, repeatability, practicability, rapidness, low cost and the like, the kit is simple in clinical sampling, the detection kit has the characteristics of simple operation process, low cost and the like, the detection time is short, the accuracy and the specificity are high, clinical popularization is easy, and the application prospect is wide. The kit can be clinically used for helping clinicians to diagnose the Alzheimer's disease in an auxiliary manner.

The present invention relates to a fluorescent detection kit for detecting hydroxocobalamin receptor antibodies in central nervous system vitamin B12 deficiency and its application, which can efficiently and accurately detect the presence and concentration of anti-CD320 antibodies in patient serum or cerebrospinal fluid. The kit uses a specific antibody to bind to the CD320 protein produced by cells expressing the CD320 gene, which then binds to a fluorescently labeled secondary antibody to generate a fluorescent signal, thereby diagnosing central nervous system vitamin B12 deficiency. The base sequence in this application ensures the effective expression of the CD320 gene, which is crucial for improving the sensitivity and specificity of the test.

The invention discloses an application of NeuroD1 (NeuroD1) in repairing Alzheimer's disease (Alzheimer's disease). The invention also discloses an application of the carrier for coding NeuroD1 in any one of the following aspects: preventing neuron damage and apoptosis; hippocampus atrophy is inhibited; the neuroinflammation is relieved; repairing blood vessel / blood brain barrier injury; the AD biomarker level of the cerebrospinal fluid is recovered to be normal; the removal of pathological toxic proteins in brain tissues is promoted; glucose metabolism is improved; the space working memory ability is enhanced; and regenerating neurons.

The invention belongs to the field of immunodetection kits, and provides a P-Tau231 single-molecule immunodetection kit based on signal amplification and application of the P-Tau231 single-molecule immunodetection kit. The kit comprises a solid-phase carrier, a detection antibody-signal amplification probe conjugate and the like, wherein a total Tau non-phosphorylated region specific first antibody is fixed on the surface of the solid-phase carrier; the detection antibody-signal amplification probe conjugate is used for recognizing P-Tau231 phosphorylated 231 sites; quantitative detection is realized by adopting a sandwich immune sandwich mode and combining with a single-molecule detection platform. The detection limit of the kit reaches fg / mL to ag / mL, and the kit has the advantages of ultrahigh sensitivity, high specificity, simplicity and convenience in operation and low sample demand, can efficiently detect P-Tau231 in cerebrospinal fluid and plasma, and is suitable for preparation of early diagnosis products for Alzheimer's disease.

The present disclosure generally relates to systems and methods of use for draining cerebrospinal fluid (CSF) from a brain or a spinal canal in a subject, for example, to treat hydrocephalus or other conditions. In some embodiments, the disclosure relates to a device comprising a flow controller positioned within a conduit that allows CSF to flow through the conduit from a first end to a second end. This may allow the CSF to drain, for example, from an intradural space (such as a thecal sac) into, for example, a paraspinal space, paraspinal vein or other venous space, or peritoneal cavity. A variety of methods may be used to hold or anchor the device in place, for example, an expansion apparatus. In some embodiments, the device can be implanted percutaneously at a location along or within a subject's spinal column, thus reducing the need for surgery, general anesthesia, and hospitalizations.

The invention relates to the technical field of curative effect prediction, in particular to a curative effect prediction method and system for treating spinal cord injury by stem cells, and the method comprises the following steps: obtaining a multi-parameter metabolism sequence and constructing an activation rhythm map, recognizing a neural restoration synchronization section, extracting a metabolism dominant path and evaluating electrical signal response, generating a para-position map layer and predicting a curative effect trend. According to the method, through introduction of cross-time-sequence metabolism and trend synchronous identification of electrophysiological indexes, dynamic mapping of stem cell activation rhythms is realized, neural axon morphological changes and cerebrospinal fluid metabolism parameters are linked, and distribution positions of key response points in a treatment cycle are determined; the method comprises the following steps: establishing a causal path based on a sequence of metabolic mutation and neural restoration events, extracting an evolution stage dominated by a metabolic driving effect, marking a matching trend of a curative effect response and an intervention path on a time axis, identifying the number and positions of trend convergence, withdrawal and interruption areas, and realizing collaborative prediction of a restoration progress and a curative effect trend.

The invention relates to the technical field of clinical detection of cerebrospinal fluid, and particularly discloses a smear device for detecting cerebrospinal fluid, which mainly comprises a sample tube and a piston assembly, the sample tube comprises a first tube body, a second tube body and a third tube body; the second pipe body is located above the first pipe body, a liquid outlet hole is formed in the bottom, and a liquid inlet hole is formed in the side wall; the bottom of the third pipe body is communicated with the liquid inlet hole through a flow channel; the piston assembly comprises a piston, a handle part and a center rod; the piston is fixedly connected with a tongue part, the center rod can be inserted into the liquid outlet hole, and the piston assembly is provided with an initial station and a flaking station. According to the smear device for detecting the cerebrospinal fluid, the manufacturing process of a cell smear is simplified, operation is convenient and fast, the smear manufacturing efficiency is remarkably improved, the smear manufacturing time is shortened, unnecessary physical damage to cells in the smear manufacturing process is avoided, then cell rupture and dissolution can be effectively reduced, and the smear quality is remarkably improved; meanwhile, the comprehensive cost of manufacturing the cell smear is obviously reduced.

This invention belongs to the field of biosensing and detection technology, specifically disclosing a Tau protein electrochemiluminescent aptamer sensor, its preparation method, and its application. The sensor uses a CsPbBr₃@PVP / Au composite material as the electrochemiluminescent substrate. A Tau protein-specific aptamer is immobilized on the substrate surface via Au-S bonds, and non-specific adsorption sites are blocked with 6-mercapto-1-hexanol. The CsPbBr₃@PVP / Au composite material is prepared by encapsulating CsPbBr₃ with PVP and then combining it with Au NPs. This invention utilizes the coordination passivation effect of PVP and CsPbBr₃ to significantly improve the aqueous stability and electrochemiluminescence efficiency of perovskite nanocrystals. Combined with the anchoring effect of AuNPs and the specific recognition effect of aptamers, it achieves ultrasensitive detection of Tau protein with a detection limit as low as 0.80 fg / mL. Furthermore, it exhibits excellent selectivity, stability, and detection accuracy in complex biological samples such as cerebrospinal fluid, providing a novel and efficient detection platform for the early diagnosis of Alzheimer's disease and showing promising clinical application prospects.

The invention relates to an instrument for transferring cerebrospinal fluid in a ventricle into a body cavity of other parts of a human body, and particularly discloses a cerebrospinal fluid drainage catheter component and a drainage system.The cerebrospinal fluid drainage catheter component comprises a catheter body, a plurality of rows of main long holes which extend in the circumferential direction and are distributed at intervals in the axial direction are formed in the wall of the catheter body, and a plurality of drainage holes are formed in the main long holes; a plurality of protruding parts are arranged on the two linear hole walls of the main long hole so that the main long hole can be divided into a plurality of micro holes. The pipe wall occupied by each row of main long holes is a first section, and the pipe wall between each two adjacent rows of main long holes is a second section; the driving component is used for driving one of every two adjacent second sections to axially move relative to the other second section, so that one end, in the circumferential direction, of the main long hole axially moves relative to the other end of the main long hole, and the two linear hole walls of the main long hole generate relative dislocation movement in the circumferential direction; therefore, the protruding part disturbs the interior of the main long hole.

Disclosed are methods for quantification of a perivascular space in a subject's central nervous system. The methods include administering contrast agent into cerebrospinal fluid of the subject; performing quantitative ultra-short time-to-echo contrast-enhanced magnetic resonance imaging (QUTE-CE MRI) on a region of interest of the subject's brain; and determining presence of the contrast agent in the perivascular space within the region of interest.

A method for improving cerebrospinal fluid clearance through a glymphatic system, while a patient is sleeping, resting, or a combination thereof, the method comprising measuring ultrasound data with one or more ultrasound emitters and extracting B-wave oscillations from the ultrasound data.

Soluble gp120 (sgp120) is associated to HIV-1-induced immune dysfunction, such as chronic immune activation. However, the detection of sgp120 in biological fluids such as plasma, serum, cervicovaginal fluids, and cerebrospinal fluids is challenging. The present application relates to novel methods and kits for the detection of sgp120 in biological fluids. These methods and kits are based on the use of specific combinations of sgp120-binding molecules recognizing particular domains of sgp120, notably the N-terminal 8-stranded β-sandwich structure, the constant region 1 and 2 (C1-C2) portion, the bridging sheet of the Co-Receptor Binding Site (CoRBS), and / or the CD4-binding domain.

Developing vehicles that efficiently deliver genes throughout the human central nervous system (CNS) will broaden the range of treatable genetic diseases. Applicants engineered an AAV capsid, BI-hTFRl, that binds human Transferrin Receptor (TfRl), a protein expressed on the blood-brain barrier (BBB). BI-hTFRl was actively transported across a human brain endothelial cell layer and, relative to AAV9, provided 40-50 times greater reporter expression in the CNS of human TFRC knock-in mice. The enhanced tropism was CNS-specific and absent in wild type mice. When used to deliver GBA1, mutations of which cause Gaucher disease and are linked to Parkinson's disease, BI-hTFRl substantially increased brain and cerebrospinal fluid glucocerebrosidase activity compared to AAV9.

The application discloses a marker group for brain glioma screening and diagnosis and application thereof, and belongs to the field of molecular biological technology. The marker group comprises at least four polypeptides shown in sequences SEQ ID NO. 1-36. The marker group constructed by the application has more excellent sensitivity and specificity when used for auxiliary diagnosis and early screening of brain glioma. The auxiliary diagnosis result of the marker group selected by the application is superior to that of an intraoperative ultrasound-based image group model (sensitivity and specificity are 81.82% and 77.78% respectively) and cerebrospinal fluid combined with blood routine detection (sensitivity and specificity are 81.0% and 94.1% respectively). The early screening result is superior to that of conventional MRI (sensitivity and specificity are 91% and 86% respectively).

The utility model discloses a cerebrospinal fluid lumbar puncture needle pressure measuring device, and relates to the technical field of medical instruments. The cerebrospinal fluid lumbar puncture needle pressure measuring device comprises an outer needle, an inner needle is arranged on the inner side of the outer needle in a penetrating mode, the outer needle comprises a pintle, a needle tube and a hollow needle, and the pintle, the needle tube and the hollow needle are communicated; the inner needle comprises a handle and a solid needle core; a flow guide opening is formed in the outer wall of the side, close to the needle tip, of the solid needle core, a flow channel is formed in the inner wall of the solid needle core and communicated with the flow guide opening, and a liquid outlet is formed in the outer wall of the side, close to the handle, of the solid needle core. By rotating the handle, the positions of the flow guide opening and the liquid outlet can be conveniently adjusted, it is ensured that cerebrospinal fluid can smoothly enter the flow channel after successful puncture and finally flow out into the pressure measuring tube and the liquid storage bag, leakage and waste of the cerebrospinal fluid are effectively avoided through the design, meanwhile, the pollution risk is reduced, and the safety of a patient is guaranteed.

The invention discloses application of a biomarker in diagnosis of lung cancer soft meningeal metastasis. According to the present invention, it is found for the first time that the metabolites such as Indolastic acid, L-Glutic acid, N-Lactoylphenylalanine, cis-Acetic acid, Formiglumic acid and N-Acetylneomic acid in the cerebrospinal fluid have good diagnosis efficiency on the lung cancer soft meningeal metastasis, have high accuracy, high sensitivity and high specificity, can be used as the biological marker of the lung cancer soft meningeal metastasis, and can be used in the effective diagnosis of the lung cancer soft meningeal metastasis. The invention provides a brand-new thought and strategy for research and development of related diagnostic products for the lung cancer soft meningeal metastasis, and has wide application prospects and important transformation significance in the technical field of diagnosis of the lung cancer soft meningeal metastasis.

The invention discloses a ventricular drainage device, and belongs to the technical field of ventricular drainage, the ventricular drainage device comprises a drainage tube main pipeline and a pressure measuring device, the lower end of the drainage tube main pipeline is provided with a one-way valve I, the drainage tube main pipeline is internally provided with a liquid medicine injection pipeline, and the liquid medicine injection pipeline is internally provided with a one-way valve II; according to the ventricular drainage device, the drainage function, the medicine injection function and the pressure measuring function are integrated, the drainage function is achieved through the drainage tube main pipeline, the medicine injection function is achieved through the liquid medicine injection pipeline, and the pressure measuring function is achieved through the pressure measuring pipeline and the pressure measuring device; according to the multifunctional integrated design, operation risks caused by replacement of multiple instruments are reduced, the clinical operation process is simplified, the treatment efficiency and safety are improved, meanwhile, reflux of liquid medicine or cerebrospinal fluid is effectively prevented through the design of the second one-way valve and the silica gel plug in the liquid medicine injection pipeline, and the risk of intracranial infection is further reduced.